Michael Dean, Ph.D.

Senior Investigator

Laboratory of Translational Genomics

NCI/DCEG

8717 GROVEMONT CIRCLE
ATC/134D
GAITHERSBURG MD 20877

240-760-6484

deanm@mail.nih.gov

Research Topics

Dr. Dean is broadly interested in inherited (germline) genetic variation, somatic mutations in tumors, and the combined effect of both on cancer risk, progression, and response to therapy. While part of the Center for Cancer Research, Dr. Dean participated in cloning genes (PTCH, VHL) involved in inherited cancers; characterized common variants associated with cancer; and sequenced the genomes of tumors to identify genes commonly altered. As Chief of LTG, Dr. Dean is expanding his work on unlocking the mechanisms through which genetic alterations affect cancer risk. By evaluating the genetic factors of tumor as well as host, Dr. Dean is determining new biomarkers for early detection and treatment. He also continues his investigations into the genetic components of cancer health disparities in the U.S. and in Latin America.

Association to Function

Genome-wide association studies have been completed on most major cancer types and have revealed many chromosome regions that influence cancer risk. We have focused on a region including the MSMB and NCOA4 genes associated with prostate cancer, and demonstrated complex regulation of expression and splicing of these genes. We are also studying variations in the TET2 gene associated with prostate cancer. TET2 is a gene mutated frequently in leukemia, and plays a role in modifications of DNA that control gene expression.

Tumor Genomes

All cancer is genetic in the sense that all tumors have genetic alterations not present in normal tissue of the person with cancer. We have sequenced the exome (coding portion of the genome) of tumors from the bladder, cervical, kidney, prostate, and adrenal gland. These data have identified potential markers for early diagnosis and targets of therapy, and a large number of somatic mutations of the genes involved in histone modification and chromatin remodeling. We will continue to explore these areas focusing on samples from the many large cohorts that DCEG has assembled. By studying samples with detailed epidemiological data we hope to better apply genetics and genomics to understanding cancer.

Health Disparities

Differences in cancer incidence and/or mortality in U.S. populations provide opportunities to learn more about specific cancers as well as to identify areas where education, improved diagnosis, and therapy can make a high impact on prevention or disease outcome. For example, in our studies of Latino/Hispanic women with breast cancer in the U.S., we have found differences in the presence and frequency of specific mutations in the BRCA1 and BRCA2 genes.

Global Health and Cancer

Cancer is increasingly a global health problem. We have established several studies in Latin America. A study of pediatric cancer seeks to understand the significant health disparity in the diagnosis of cancer among the indigenous Mayan children of Guatemala. And studies of cervical and breast cancer in Guatemala, Nicaragua, Mexico and Venezuela are yielding important genetic differences as well as potential environmental factors.

For common cancers among adults, we are investigating the reasons behind the very high rates of cervical cancer in the region. We apply a molecular and genomic approach to this question, analyzing cancer tissue, blood samples, and standard epidemiological information on cases as well as genome sequencing. 

Biography

Dr. Michael Dean is the Chief of the Laboratory of Translational Genomics. He obtained his Ph.D. from the Biochemistry Department at the Boston University School of Medicine. He performed his postdoctoral studies at the National Cancer Institute, Center for Cancer Research (CCR), on the MET oncogene and cystic fibrosis gene. He is a member of the American Society of Human Genetics, Centre d'Etude du Polymorphisme Humaine (CEPH), the Human Genome Organization (HUGO), and an adjunct faculty member at Hood College. Before joining DCEG in 2015, Dr. Dean led the Human Genetics Section of the Cancer and Inflammation Program within CCR.

Selected Publications

  1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059-65.

  2. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, Wainwright B, Bale AE. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841-51.

  3. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273(5283):1856-62.

  4. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004;350(13):1296-303.


This page was last updated on January 17th, 2017